sur Jaguar Health, Inc. (NASDAQ:JAGX)
Jaguar Health's Canalevia-CA1 Featured in PetVet Magazine
Jaguar Health, Inc. announced that Canalevia-CA1, its prescription drug for treating chemotherapy-induced diarrhea (CID) in dogs, is featured in PetVet Magazine. Canalevia-CA1 is FDA conditionally approved and the first drug of its kind for dogs. Its active ingredient is crofelemer, derived from the Croton lechleri tree. Crofelemer is also under investigation in humans for cancer therapy-related diarrhea.
Lisa Conte, Jaguar's CEO, highlighted the significance of managing related diarrhea, which impacts the treatment and quality of life in both humans and animals with cancer. Canalevia-CA1 is for dogs only and must be prescribed by a licensed veterinarian. Common side effects include decreased appetite, activity, and abdominal pain.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Jaguar Health, Inc.